Positive CHMP opinion paves way for Lundbeck's Vyepti in Europe

Lundbeck's migraine treatment Vyepti should be approved in Europe, according to the EMA's expert committee (CHMP), which evaluated the pharmaceutical company's marketing application during its November meeting.

Photo: Torben Klint/Ritzau Scanpix

Lundbeck is a huge step closer to realizing its launch of the migraine drug Vyepti on the European market.

On Friday, the pharmaceutical company announced that the European Medicines Agency's expert committee (CHMP) has nominated the intravenous (IV) infusion treatment for approval in the EU.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs